Forward Pharma A/S Announces Termination of its American Depositary Receipts (“ADR”) Facility
January 08, 2024 16:00 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Forward Pharma A/S (“Forward” or the “Company”) today announced that its Board of Directors has approved a termination of the Deposit...
Forward Pharma A/S Announces Change in Ratio of American Depositary Shares to Ordinary Shares
June 07, 2023 08:30 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, June 07, 2023 (GLOBE NEWSWIRE) -- Forward Pharma A/S (OTC:FWPAY) (“Forward” or the “Company”) today announced that its Board of Directors has approved a change in the number of...
Forward Pharma Announces Expected Delisting of its American Depositary Shares from the Nasdaq Capital Market
December 19, 2022 06:00 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we” or “Forward”), today announced that that on December 16, 2022 it received written notice from The Nasdaq...
Forward Pharma Announces the Decision of the Enlarged Board of Appeal of the European Patent Office in the EP2801355 Petition for Review
December 06, 2022 14:00 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“Forward” or the “Company”), today announced that the Enlarged Board of Appeal (the “EBA”) of the European...
Forward Pharma Reports Financial and Operating Results for the Year Ended December 31, 2021
April 08, 2022 17:25 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, April 08, 2022 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported...
Forward Pharma Announces the Decision of the Technical Board of Appeal of the European Patent Office in the EP2801355 Appeal Hearing
September 06, 2021 10:21 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, Sept. 06, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that the Technical Board of Appeal (the “TBA”) of the...
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2020
April 14, 2021 16:40 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, April 14, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported...
Forward Pharma Announces Rescheduling of the EP2801355 Appeal Hearing to September 6, 2021 due to COVID-19 Restrictions
January 12, 2021 16:30 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, Jan. 12, 2021 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to ongoing precautionary measures against the...
Forward Pharma Announces New Date for the EP2801355 Appeal Hearing due to COVID-19
May 12, 2020 17:00 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, May 12, 2020 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“we,” “Forward” or the “Company”), today announced that due to current precautionary measures against the...
Forward Pharma Reports Financial and Operational Results from the Year Ended December 31, 2019
April 24, 2020 16:50 ET
|
Forward Pharma A/S
COPENHAGEN, Denmark, April 24, 2020 (GLOBE NEWSWIRE) -- Forward Pharma A/S (NASDAQ:FWP) (“We,” “Forward” or the “Company” and, together with its subsidiaries, the “Group”), today reported...